2
Clinical Trials associated with Fecal Microbiota(University of Pittsburgh) / Not yet recruitingPhase 2IIT Randomized Phase II Study of Pembrolizumab/Lenvatinib with and Without Responder-derived FMT (R-FMT) in Relapsed/Refractory Melanoma
In this is a randomized phase II study the addition of R-FMT to pembrolizumab /lenvatinib in PD-1 R/R melanoma will be evaluated over a 104-week period in patients with anti-PD-1 R/R disease. Patients with PD-1 refractory advanced melanoma are eligible to enroll, excluding patients with prior lenvatinib (or other TKI) exposure. Intestinal microbiome composition mediates response to anti-PD-1 by affecting systemic inflammatory tone.
Phase II Feasibility Study of Fecal Microbiota Transplant (FMT) in Advanced Melanoma Patients Not Responding to PD-1 Blockade
The main goal of this research study is to determine if the fecal microbiota transplant (FMT) improves the body's ability to fight your cancer.
100 Clinical Results associated with Fecal Microbiota(University of Pittsburgh)
100 Translational Medicine associated with Fecal Microbiota(University of Pittsburgh)
100 Patents (Medical) associated with Fecal Microbiota(University of Pittsburgh)
100 Deals associated with Fecal Microbiota(University of Pittsburgh)